Chairman's Profile
Being different and making a difference. That sums up the vision, philosophy, conviction and driving force behind Dr. Habil F Khorakiwala who revels in venturing down the road less travelled.
He founded Wockhardt in 1967. Today, the Wockhardt Group is India’s leading research-based, global healthcare enterprise with relevance in the fields of Pharmaceuticals, Biotechnology, Active Pharmaceutical Ingredients (APIs), and Super Speciality Hospitals.
Investor Information
Our investors, Wockhardt shareowners, are an important and valued constituent of the Wockhardt stakeholder universe.
While it is a matter of regulatory compliance, we also consider it as good governance and our duty and responsibility, to keep our investors informed and updated regularly about news, events and developments that impact our business and operations.
Investor Focus
FINANCIAL RESULTS FY23 Q3
FINANCIAL RESULTS FY23 Q2
FINANCIAL RESULTS FY23 Q1
About Us
Wockhardt is a leading, research-based, global enterprise with relevance in the fields of pharmaceuticals, biotechnology, and healthcare services.
Our multinational R&D and manufacturing facilities are spread across India, USA, UK and UAE, and our worldwide marketing presence includes over 30 countries across 6 continents.
Our Products
-
Heparin Sodium Flushing Solution (previously known as Canusal
Know More -
Heparin Sodium 5000 I.U./ml (previously known as Multiparin
Know More -
Heparin Sodium Flushing Solution (previously known as Canusal
Know More -
Heparin Sodium Flushing Solution (previously known as Canusal
Know More -
Heparin Sodium Flushing Solution (previously known as Canusal
Know More
-
Heparin Sodium Flushing Solution (previously known as Canusal
Know More -
Heparin Sodium 5000 I.U./ml (previously known as Multiparin
Know More -
Heparin Sodium Flushing Solution (previously known as Canusal
Know More -
Heparin Sodium Flushing Solution (previously known as Canusal
Know More -
Heparin Sodium Flushing Solution (previously known as Canusal
Know More
Media & Press
Team Wockhardt
OUR DISCOVERY. ROAD TO RECOVERY.
Life threatened globally by rising multidrug-resistant
infections or Antimicrobial Resistance (AMR).
WCK 5222 administered on compassionate ground and
saved 20 lives. Now in Global phase III clinical trial.
Research Wins. Life Wins.
Life Wins
Global Reach
Our Pharma Portfolio
INVESTOR FOCUS
FINANCIAL RESULTS FY23 Q4
FINANCIAL RESULTS FY23 Q3
FINANCIAL RESULTS FY23 Q2
WOCKHARDT’S Q4 FY23 3 FOLD JUMP IN EBITDA OVER Q4 FY22
WOCKHARDT’S Q3 FY23 EBITDA GROWTH @37% OVER Q2 FY23
WOCKHARDT’S Q2 FY23 TOPLINE GROWTH @14% AND EBITDA GROWTH @369% OVER PREVIOUS QUARTER
Media Coverage
Beyond Pharmaceuticals
6 new drugs under development, accorded QIDP status by US FDA and in Phase III clinical stage, are being developed as novel antibiotics and are expected to significantly aid global efforts against Antimicrobial Resistance (AMR).
A chain of super-speciality hospitals offering world-class tertiary and quaternary healthcare services, Wockhardt Hospitals has built a reputation for quality, professionalism and positive outcomes.
A chain of super-speciality hospitals offering world-class tertiary and quaternary healthcare services, Wockhardt Hospitals has built a reputation for quality, professionalism and positive outcomes.
